Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Ebola virus vaccine (Primary) ; GSK 3390107A (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2016.
- 01 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.